Educational resources

This section includes resources developed by Guidelines, including algorithms, medicines appraisal cards, supplements, and videos. Items may contain pharmaceutical promotional information.

20220124 On demand HRT webinar SPIN block_V.1

Hormone replacement therapy (HRT): Overview and focus on progestogens

Commissioned by Viatris

This promotional webinar has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0346 March 2022

Norgine logo

Managing iron deficiency anaemia

Commissioned by Norgine Pharmaceuticals Limited

Information intended for UK healthcare professionals only. These promotional videos have been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines and Guidelines LivePromotional information regarding Norgine Pharmaceutical Limited products will be presented.
View FERACCRU® (ferric maltol) prescribing information and adverse event reporting information here
UK-HAE-FER-2200012
Date of preparation: May 2022

20220124 HRT video SPIN block_V.1

Hormone replacement therapy (HRT): what is the role of the progestogen?

Commissioned by Viatris

This promotional video has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals. Products and brand names are mentioned. View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0362 March 2022

Dickman index image

Targeting the cause of opioid-induced constipation with PAMORAs

Commissioned by Sandoz Limited

This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141580 | Date of preparation: September 2021

FINAL video image

Management of obesity in primary care: a Guidelines algorithm

Funded by Novo Nordisk Limited

Information intended for UK healthcare professionals only. These videos have been funded through an arm’s-length sponsorship by Novo Nordisk Limited. Guidelines approached Novo Nordisk Limited to fund the production of these videos. 
Date of preparation: December 2021

Pali Hungin index image

Diagnosis and initial management of opioid-induced constipation

Commissioned by Sandoz Limited

This promotional video has been funded by Sandoz Ltd and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141579 | Date of preparation: September 2021

20-SZ-4809 index image_v1

Opioid-induced constipation: optimal management and the role of PAMORA drugs

Commissioned by Sandoz Limited

These promotional videos have been funded by Sandoz Ltd and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View prescribing information
141578 | Date of preparation: September 2021

foreign bodies index image

Management of common eye conditions: corneal and subtarsal foreign bodies

Funded by Allergan plc

Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) covers the symptoms and treatment of foreign bodies in the eye.

eye drop demo image

Management of common eye conditions: Glaucoma and the #knowyourdrops campaign

Funded by Allergan plc

Sarah Thomas (Moorfields Eye Hospital NHS Foundation Trust) discusses treatment of glaucoma and techniques for correct eye drop administration.

Dr Glenis Scadding Guidelines Live 2018

Dr Glenis Scadding Q&A on rhinitis

By

This session was supported by an educational grant from Mylan Ltd. Dr Glenis Scadding comments on the main presentations of rhinitis, its impact on patients’ daily lives, red flags for referral, and the main recommendations of the 2017 BSACI guideline

Dr Kevin Fernando Guidelines Live 2018

Dr Kevin Fernando Q&A on type 2 diabetes

By

Dr Kevin Fernando answers questions on the impact of type 2 diabetes on patients’ daily lives, differences between NICE and SIGN guidance, and key take-home messages for primary care

20220614_Saxenda SMC card digital update_v1

Liraglutide 6 mg/ml solution for injection in pre-filled pen (Saxenda®) SMC2455

Commissioned by Novo Nordisk Limited

Information intended for UK healthcare professionals only. The production of this Guidelines card has been commissioned by Novo Nordisk Limited.
View Saxenda® (liraglutide 3 mg) Great Britain and Northern Ireland prescribing information and adverse event reporting information.
UK22SX00249
Date of preparation: June 2022

Final version_Sixmo SMC card

Sixmo®▼ (buprenorphine) 74.2mg implant SMC2372

Commissioned and funded by Accord Healthcare Limited

The production of this Guidelines card has been commissioned by Accord Healthcare Limited.
View adverse event reporting and prescribing information
UK-03735 April 2022

20220721 Trixeo PSC - digital

Trixeo® Aerosphere® (formoterol fumarate, glycopyrronium, and budesonide)

Commissioned and funded by AstraZeneca Limited

This promotional prescribing summary card has been developed from content provided by AstraZeneca Limited. Information intended for UK healthcare professionals only.
View Trixeo (formoterol fumarate dihydrate/ glycopyrronium/ budesonide) prescribing information and adverse event reporting information
View Bevespi (glycopyrronium/formoterol fumarate dihydrate) prescribing information and adverse event reporting information
GB-37843
Date of preparation: July 2022

Alliance Forceval PSC_digital index image

Malnutrition and FORCEVAL® Capsules

Commissioned by Alliance Pharmaceuticals Ltd

This prescribing summary card was developed from content provided by Alliance Pharma in a format developed by Guidelines Information intended for UK healthcare professionals only.
View Forceval® Capsules prescribing and adverse event reporting information.
JB-001493 June 2022

DuoResp Spiromax (budesonide:formoterol) prescribing summary card

DuoResp® Spiromax® (budesonide/formoterol)

Commissioned by Teva UK Limited

This promotional prescribing summary card has been developed from content provided by Teva UK Limited. Information intended for UK healthcare professionals only.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Teva UK Limited on 0207 540 7117 or medinfo@tevauk.com.

Click here for prescribing information and adverse event reporting

DUOR-GB-00117
Date of preparation: March 2022

Final version_L'Oreal acne webinar report

WEBINAR REPORT: Best practice: Management of mental health in patients with acne

Commissioned by L'Oréal (UK) Limited

This report and the webinar have been commissioned and funded by L’Oréal (UK) Limited and developed in partnership with Guidelines and Guidelines in Practice.
June 2022

RICOCHET study supplement

A national audit of pancreatic enzyme replacement therapy (PERT) prescribing in patients with pancreatic cancer: The RICOCHET study

Commissioned by Viatris

This supplement has been commissioned and funded by Viatris and developed in partnership with Guidelines
NON-2021-4065 February 2022

Measuring blood sugar on finger_AS

Best practice treatment and management of patients with type 2 diabetes, cardiovascular disease, and heart failure

By Development Group—Javaid (Chair) Anand Assomull Holmes Karalliedde

This management algorithm was developed by a multidisciplinary expert panel: Javaid et al with the support of an educational grant from AstraZeneca. Information intended for UK healthcare professionals.

Final version - HE algorithm

Management of hepatic encephalopathy in primary care

Commissioned by Norgine Pharmaceuticals Limited

This management algorithm has been commissioned and funded by Norgine Pharmaceuticals Limited and developed in partnership with Guidelines. Information intended for UK healthcare professionals only.
View TARGAXAN® (rifaximin-α) prescribing and adverse event reporting information
UK-HEP-XIF-2100040  October 2021

A nurse consulting with a woman in WPG Yellow

Guideline for the managed introduction of biosimilar bolus insulin in individuals with type 2 diabetes

By Working party–Down Beba Davies Diggle Goel

This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Sanofi Ltd.

Viatris HRT algorithm supplement_Index image

Prescribing combined hormone replacement therapy (HRT) containing dydrogesterone

Commissioned by Viatris

This promotional algorithm has been commissioned and funded by Viatris and developed in partnership with Guidelines. Intended for UK healthcare professionals.
View Femoston® (estradiol/dydrogesterone) and Femoston® -conti (estradiol/dydrogesterone) prescribing and adverse event reporting information.
FEM-2021-0238 June 2021

Stack of fruits, white weight scale and tailor meter on wooden board_AS

Managing obesity in primary care

By Development Group—Tahrani Parretti O’Kane Chowhan Ratcliffe and Le Brocq

This management algorithm was developed by a multidisciplinary expert panel: Tahrani et al with the support of an educational grant from Novo Nordisk Limited. Information intended for UK healthcare professionals.

AdobeStock_212764468

Identifying and managing allergic rhinitis in the asthma population

By Development Group—Scadding Holmes Ryan and Williams

This management algorithm was developed by a multidisciplinary expert panel: Scadding et al with the support of an educational grant from Mylan.

An inhaler in WPG Yellow

Inhaler choice guideline

By Development group—Usmani Capstick Saleem Scullion

This management algorithm was developed by a multidisciplinary expert panel: Usmani et al and supported by Chiesi Ltd through the provision of a grant for its production.

Preconception advice

Women of child-bearing age with inflammatory rheumatic diseases guideline

By Working party—Giles Allen Nelson-Piercy Tower Warburton Gordon

This guideline was developed by a multidisciplinary expert panel: Giles I et al with the support of an educational grant from UCB Pharma Ltd.

Doctor talking to male patient in office

Guideline for the managed introduction of biosimilar basal insulin

By Working party—Down Beba Brown Diggle Goel Milne

This guideline was developed by a multidisciplinary expert panel: Down S et al with the support of an educational grant from Mylan.

Nurse giving patient water use glass syringe to irrigate nasogastric tube in hospital

Medication management of patients with enteral feeding tubes

By Working party—Wright Griffith Merriman Smithard Smyth Welsh

This guideline was developed by a multidisciplinary expert panel: Wright D et al with the support of a grant from Rosemont Pharmaceuticals Ltd.

22-BM-330474 Index image

Anticoagulation management for elderly patients with NVAF, CKD and other comorbidities

Developed and funded by the Bristol Myers Squibb/Pfizer Alliance

This promotional webinar was organised and funded by the Bristol Myers Squibb/Pfizer Alliance and is intended for UK healthcare professionals only.
Click HERE to view ELIQUIS (apixaban) prescribing information and adverse events reporting

Adverse events should be reported. Reporting forms and information can be found at: UK – www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card in the Google Play or Apple App Store Adverse events should also be reported to Bristol-Myers Squibb via medical.information@bms.com  or 0800 731 1736 (UK).

432-GB-2200204  May 2022

Guidelines supplements are written by experts and typically discuss a piece of national guidance, pulling out key learning points for GPs.

Index image

Identify, optimise treatment, refer—treating familial hypercholesterolaemia (FH) in primary care

Commissioned by Amgen Ltd

This eLearning module has been commissioned and funded by Amgen Ltd and developed in partnership with Guidelines.
By logging in to this page you confirm your understanding that you are about to view content intended for UK HCPs only. 
The content has been developed in collaboration with, and funded by, Amgen Ltd.
SC-UKIE-AMG145-00785 | December 2021

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes

Managing patients with non-valvular atrial fibrillation (NVAF) and diabetes—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2416 March 2022

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants

Transitioning eligible patients with NVAF from warfarin to direct oral anticoagulants—a patient case study

Commissioned by Bayer plc

This promotional Learning module has been commissioned and funded by Bayer plc and developed in partnership with Guidelines.
View adverse event reporting and prescribing information for Xarelto(rivaroxaban)   
PP-XAR-GB-2415 January 2022

Index image

Management of venous thromboembolism in primary care

Commissioned by Bristol Myers Squibb on behalf of the BMS – Pfizer Alliance

This promotional eLearning module has been funded by Bristol Myers Squibb on behalf of the BMS / Pfizer Alliance and developed in conjunction with Guidelines.  The promotional content on this page is intended for UK healthcare professionals only.
View ELIQUIS (apixaban) prescribing and adverse event reporting information
432-GB-2100953 | February 2022